These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 37184408)
1. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408 [TBL] [Abstract][Full Text] [Related]
2. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates. Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060 [TBL] [Abstract][Full Text] [Related]
3. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022). Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826 [TBL] [Abstract][Full Text] [Related]
4. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Shortridge D; Kantro V; Castanheira M Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238 [TBL] [Abstract][Full Text] [Related]
5. Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates. Tamma PD; Bergman Y; Jacobs EB; Lee JH; Lewis S; Cosgrove SE; Simner PJ; Infect Control Hosp Epidemiol; 2023 May; 44(5):762-767. PubMed ID: 35822340 [TBL] [Abstract][Full Text] [Related]
6. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales. Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303 [TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam. Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076 [TBL] [Abstract][Full Text] [Related]
8. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022). Sader HS; Mendes RE; Duncan L; Kimbrough JH; Carvalhaes CG; Castanheira M Diagn Microbiol Infect Dis; 2023 Jun; 106(2):115945. PubMed ID: 37060707 [TBL] [Abstract][Full Text] [Related]
9. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam. Bonnin RA; Bernabeu S; Emeraud C; Creton E; Vanparis O; Naas T; Jousset AB; Dortet L Int J Antimicrob Agents; 2022 Oct; 60(4):106660. PubMed ID: 35988666 [TBL] [Abstract][Full Text] [Related]
10. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020. Chang CY; Lee YL; Huang YT; Ko WC; Ho MW; Hsueh PR Int J Antimicrob Agents; 2023 Jun; 61(6):106815. PubMed ID: 37059343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]